SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 13, 2023 08:18 ET
|
SciSparc Ltd
MitoCareX Bio met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
SciSparc Granted European Patent for its Core Technology
October 03, 2023 07:33 ET
|
SciSparc Ltd
The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 07, 2023 09:15 ET
|
SciSparc Ltd
Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 30, 2023 09:25 ET
|
SciSparc Ltd
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 ...
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 21, 2023 09:00 ET
|
SciSparc Ltd
Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
March 09, 2023 07:30 ET
|
SciSparc Ltd
Israeli Ministry of Health granted an approval to use SCI-110 in a clinical trial at the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) --...
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
March 06, 2023 07:45 ET
|
SciSparc Ltd
TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...